Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05012397 · OUTCOME

Duration of Response (DOR)

Milademetan in Advanced/Metastatic Solid Tumors · Source last updated 2024-10-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
months
Interval / dispersion
Not reported
Time frame
From start date of response to first PD or study completion date; up to 23.5 months

What was measured

DOR defined as the time from the date of first documentation of CR or PR according to RECIST v1.1 to the date of disease progression or death due to any cause according to Investigator assessment

Analysis population: This analysis is conducted in all participants within the Centrally confirmed population (CCP) who had a confirmed CR or PR.

Groups in this outcome

Milademetan (RAIN-32)

260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Milademetan (RAIN-32)1

Reported measurements

Source class 1
Values in months · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Milademetan (RAIN-32)3.84Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3.84
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
DOR defined as the time from the date of first documentation of CR or PR according to RECIST v1.1 to the date of disease progression or death due to any cause according to Investigator assessment
groups
  1. description
    260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
    id
    OG000
    title
    Milademetan (RAIN-32)
param Type
NUMBER
population Description
This analysis is conducted in all participants within the Centrally confirmed population (CCP) who had a confirmed CR or PR.
reporting Status
POSTED
time Frame
From start date of response to first PD or study completion date; up to 23.5 months
title
Duration of Response (DOR)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice